Avacta Group Plc

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:14 09/07/2025 pm IST			5-day change	1st Jan Change
31.50 ^GBX	0.00%		+3.28%	-37.00%

04/07	Avacta Group Plc - Shareholder/Analyst Call
03/07	IntelliAM wins order; Schroder BSC mulls options	AN

Avacta Therapeutics' AVA6000 Phase 1a Dose Escalation Shows Early Efficacy

Published on 07/03/2025 at 15:10

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Avacta Group Plc

Avacta Group Plc - Shareholder/Analyst Call	04/07
IntelliAM wins order; Schroder BSC mulls options	03/07	AN
EXECUTIVE CHANGES: Avacta names CMO, Mission Group appoints CEO	02/07	AN
Avacta Group Names Chief Medical Officer	01/07	MT
Avacta Group plc Appoints David Liebowitz as Chief Medical Officer	01/07	CI
Avacta Group plc Announces New Response in the FAP-Dox Phase 1B Trial	19/06	CI
Journeo in New York deal; Anpario to meet market view	19/06	AN
Avacta Group Announces New Partial Response In FAP-Dox Phase 1b Trial	19/06	RE
Avacta Group Plc - Special Call	11/06
Avacta Group Plc, 2024 Earnings Call, Jun 06, 2025	07/06
Avacta revenue falls, sees "transformative" year after repositioning	06/06	AN
Avacta Therapeutics Says FAP-Dox Initial Data In Salivary Gland Cancer Expected Late 2025	06/06	RE
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2024	06/06	CI
Avacta Group Plc Announces Board Appointments	06/06	CI
Avacta Group Plc Auditor Raises 'Going Concern' Doubt	06/06	CI
Avacta Group plc Announces Changes to Its Board, Effective Date Is April 30, 2025	29/04	CI
Avacta Therapeutics Presents Data from Lead Pre\|Cision® Candidate Fap-Dox At the 2025 Aacr Annual Meeting	28/04	CI
Avacta Therapeutics Issues Shares for Bond Repayment	23/04	MT
Avacta Group Says Ava6103 Phase 1 Trial To Begin Q1 2026	31/03	RE
Avacta Therapeutics Finalizes UK Diagnostics Unit Sale	25/03	MT
Duo-Med Group Belgium completed the acquisition of Launch Diagnostics Holdings Limited from Avacta Group Plc.	25/03	CI
Avacta Group Plc - Special Call	14/03
Avacta sells Launch Diagnostics; reports "promising" efficacy data	07/03	AN
Avacta Therapeutics to Sell UK Diagnostics Unit for GBP13 Million	07/03	MT
AIM WINNERS & LOSERS: Avacta makes progress on AVA6000 testing	07/03	AN

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Employees

151

Sector

Biotechnology & Medical Research

Calendar

25/09 - Q2 2025 Earnings Release (Projected)

More about the company